The Council on the Kidney in Cardiovascular Disease of the AHA recognized the need for a summary of current evidence on the cardiorenal benefits with SGLT2 inhibitors and GLP-1 receptor agonists in patients with chronic kidney disease (CKD) and T2DM. Together with other councils of the AHA, they published a scientific statement on this topic.

Newer classes of diabetes agents, including SGLT2 inhibitors and GLP-1 receptor agonists have changed the landscape of therapeutic options for patients with chronic kidney disease (CKD) and T2DM. Trials with these agents have demonstrated reductions in CV adverse events and progression to end-stage kidney disease. Although exact mechanisms are unclear, several potential mechanisms have been suggested which mediate the beneficial effects of these drug classes, possible independent of antihyperglycemic effects.

This scientific statement summarizes the current literature, reviews relevant potential mechanisms, and provides a practical clinical decision-making algorithm, prescribing information and a proposed collaborative care model for cardiologists, nephrologists, diabetologists, and internists to facilitate prompt and appropriate integration of these drug classes in the management of patients with CKD and T2DM.

Find this statement online at Circulation